Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Cancer Res. 2015 Dec 9;22(7):1572–1582. doi: 10.1158/1078-0432.CCR-15-1965

Figure 5. Ibrutinib decreases migration of CLL cells to bone marrow supernatant.

Figure 5

A, The percent changes in the evaluated chemokines in bone marrow supernatant at eight weeks (black) and 24 weeks (grey) of ibrutinib treatment compared to baseline, n=11. Shown is the mean with SEM. B, PBMCs collected pre-ibrutinib evaluated for migration towards autologous BM supernatant collected pre-treatment and after eight weeks on ibrutinib, n=8. W: weeks on treatment, PRE: baseline. Statistical analyses were determined by Wilcoxon matched-pairs signed rank test for A, by Student’s paired t-test for B. Asterisks indicate degree of statistical significance compared to PRE: * P < .05 and ** P < .01.